The combination of immunostimulatory plasmid DNA encoding IL-2 and siRNA delivered by TT-LDCP NPs targeting PD-L1 in the treatment of hepatocellular carcinoma (HCC) has also been shown to significantly increase tumor infiltration and CD8+ T-cell activation (37). This evidence concerns the gene IL2 and hepatocellular carcinoma.